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million. Within the adjunct group, growth factors (at
4.2%) accounted for the largest proportion of the cost in-
crease, while antiemetics (the largest dollar amount) de-
creased between 1995 and 1998. CONCLUSION: Che-
motherapy accounted for the majority of the total increase
in pharmaceutical cost in-patients with cancer. Drugs
used in the treatment of routine conditions (i.e., not can-
cer-related) were the second largest cost drivers. Support-
ive therapy was the third largest cost driver. Of the groups
studied, chemotherapy adjuncts had the smallest impact
on total drug cost increases.
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OBJECTIVE: To determine treatment patterns and cost
associated with the management of lung cancer in France
from the perspective of French hospitals by means of a
retrospective chart review. METHODS: Estimates were
based on a retrospective review of medical care consump-
tion in patients diagnosed with either small cell lung can-
cer (SCLC) or non small cell lung cancer (NSCLC) be-
tween 06/98 and 06/99 and followed until 09/99. Quotas
were defined by type and stage of lung cancer according
to available epidemiological data. Patients were identified
at a representative sample of 11 hospital centres in
France. Costs were estimated from date of diagnosis until
death or 16 months follow-up. Costs were adjusted for
censoring by means of a method described by Lin et al.
(Biometrics, 1997). RESULTS: 439 patient charts were
reviewed, including 92 SCLC and 357 NSCLC. Mean age
at diagnosis was 62, sex ratio was 82% male, 18% fe-
male. Survival at 12 months was 36% for SCLC and
ranged between 79% and 32% for NSCLC depending on
stage at diagnosis. All patients with limited-stage SCLC
received chemotherapy and 84% benefited from radio-
therapy. Of patients with disseminated SCLC, 91% re-
ceived chemotherapy and 49% palliative radiotherapy.
Patients with stage I–III NSCLC were treated with sur-
gery (43%), chemotherapy (71%) and/or radiotherapy
(73%). Stage IV NSCLC patients had surgery (15%) and/
or chemotherapy (91%) and/or radiotherapy (65%). Pre-
liminary analyses indicate that the management of ad-
verse events accounted for more than 25% of the total
cost. CONCLUSION: Considering the high cost manage-
ment of adverse events and radiotherapy, new chemo-
therapy treatments increasing overall survival with ac-
ceptable toxicity profile and decreasing radiotherapy acts,
would have a significant economic value. Updated results
will be presented.
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OBJECTIVES: To study the cost of cancer pain manage-
ment in the Maccabi database. This database delivers in-
formation on diagnosis, treatment and costs. Costs were
compared for patients that were on MOR and switched
to FEN and costs were assessed relative to total treatment
cost. METHODS: A selection was made of all cancer pa-
tients (N  1082) treated with strong opioids during
1997–1998. Fifty-two percent were women and average
age 62 years. Fifteen percent of the patients had skin can-
cer and 10% was reported with lung cancer. Patients
were divided in four different groups based upon the se-
quence of strong opioid use: FF is the group that was on
FEN, MF was the group that started on MOR but
switched to FEN, FM vice versa and MM were on MOR
throughout. RESULTS: In the MF group significantly
fewer infections and abdominal pain were reported by
patients after switching to FEN. Also a reduction in
drugs used was observed after switching to FEN: laxa-
tives, H2-blockers, anti-emetics, anti-diarrhea, antibiot-
ics, NSAIDs and other pain treatments. The total mean
daily drug acquisition cost was 162 New Israelian Shekel
(NIS) for the MOR period and 115 NIS while on FEN, a
reduction resulting from reduced need for concomittant
medication. The cost for pain management accounted for
3.1% (MM) to 6.7% (MF) of the total expenses, indicat-
ing the relatively low impact the choice of pain strategy
has on total cost. CONCLUSION: This database analysis
indicates that FEN treatment generates fewer costs com-
pared to MOR treatment in patients switching from
MOR to FEN. Without an adequate control group it is
difficult to determine whether this reflects resource utili-
zation related to the selected pain treatment or changed
medical practice in the course of cancer treatment. Over-
all the cost of pain management is low relative to the to-
tal cost for these patients.
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QoL is an important factor in the evaluation of new can-
cer therapies. Conventional analyses of responses in ther-
apeutic trials fail to account for treatment effects on pa-
tient’s perception of their health status and their general
well being. OBJECTIVE: To develop a methodology for
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integration of both quantity and quality of life into a single
analysis to be used for treatment comparisons. METHODS:
EORTC QLQ C-30, FACT-G&P were used to collect
QoL data for 288 subjects with asymptomatic hormone
refractory prostate cancer as part of a randomized, dou-
ble-blind, placebo-controlled dose ranging study of atra-
sentan, a selective endothelin-A receptor antagonist. Both
instruments were administered at baseline and then at ev-
ery six weeks until disease progression. The missing QoL
domain scores were imputed by last observation carried
forward method. The QoL domain scores were converted
to a unit scale, range 0–1, with a higher score indicating
improved QoL. The conversion was implemented with a
linear affine transformation of original score according
to Ware et. al. Each subject’s QADFS was computed as
the sum of the product QoL weights and the duration for
which the patient experienced that level of QoL. These
QADFS times were then analyzed with Kaplan-Meier
methodology. In order to analyze the effect of adminis-
trative censoring on the results an area under the curve
analysis for each QoL domain was implemented with the
assumption of equal length of follow-up (365 days). RE-
SULTS: The mean QADFS were estimated and compared
amongst the three treatment groups. These comparisons
yielded results that were robust to the choice of QoL do-
mains and the length of follow-up. CONCLUSIONS: Multi-
dimensional QoL instruments may be used to provide a
summary index for assessing the response of novel inter-
ventions for cancer patients. It accounts for patient’s QoL
for the duration of the trial unlike the traditional (e.g.,
ANOVA) methods of analyses.
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RENAL DISORDERS
PGU1
IS HEALTH-RELATED QUALITY OF LIFE (HRQL) 
IMPROVED BY GASTRO-ESOPHAGEAL REFLUX 
DISEASE (GERD) DRUGS?
Chassany O, Duracinsky M, Bergmann JF
Therapeutic Research Unit, Hopital Lariboisiere, Paris, France
OBJECTIVE: Effective antisecretory drugs are available
to treat GERD, and result in dramatic improvement of
pyrosis over placebo. Assessing a similar improvement of
HRQL would appear of value. METHOD: A critical ap-
praisal of published controlled trials was performed us-
ing a checklist. RESULTS: Although trials comparing
proton pump inhibitors (PPI) to placebo or to H2-block-
ers or cisapride showed a clinically significant difference
in the rate of complete relief of pyrosis, none was able to
show a clear and unbiased HRQL improvement. For
each trial, several or all of the following issues that may
help one to have confidence in study results are not pre-
sented or are missing: justification of the choice of ques-
tionnaires; hypotheses of changes in HRQL scores and
power estimation (even if HRQL assessment is a second-
ary endpoint); justification of the use of several question-
naires (are they covering different concepts?); statistical
analysis plan; description and imputation of missing data,
and intent to treat analysis (e.g. 408 patients among 599
randomized in a trial are analyzed for HRQL with no ex-
planation about missing data); adjustment for multiple sta-
tistical comparisons; presentation of all the scores. Generic
questionnaires (Psychological General Well Being is the
most frequently used) result most often in non significant
differences or findings without clinical significance (effect
size  0.30). This raises the uncertainty of questionnaire
responsiveness, knowing that pyrosis is largely improved
and that the sample size of trials ranges from 300 to 800.
Using the specific questionnaire, Gastrointestinal Symp-
tom Rating Scale, leads to significant results, but it may be
argued that this questionnaire is not simply a symptom
scale, because only two items on the questionnaire concern
bother about pyrosis and regurgitation. CONCLUSION:
There is concern to conclude that despite a large improve-
ment of pyrosis, especially with PPI, there is no definite
demonstration that HRQL is improved in GERD.
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OBJECTIVE: Patient-reported symptom severity mea-
sures are important for evaluating the effectiveness of
treatments for gastrointestinal diseases because they are
the only measures in clinical evaluation that directly re-
flect the patient experience. The objective of this study is
to describe the development and initial testing of a new
patient self-report instrument, the Patient Assessment of
Upper GastroIntestinal Disorders-Symptom Severity In-
dex (PAGI-SYM) in subjects with gastroesophageal re-
flux disease (GERD) or dyspepsia. METHODS: Instru-
ment content was based on an extensive review of the
published literature and interviews with patients and cli-
nicians. A sample of 448 persons with GERD (249) or
dyspepsia (199) were identified and recruited from a
large population survey. Using telephone interviews, sub-
jects completed the PAGI-SYM, the SF-36, and a measure
of patient-rated change in GI-related symptoms, the
Overall Treatment Effect Scale (OTE). Two-week repro-
ducibility was evaluated in 68 subjects. RESULTS: The
37-item PAGI-SYM is comprised of 6 subscales: heart-
burn, reflux/regurgitation, nausea/vomiting, abdominal
pain, bloating/early satiety, and other symptoms. Sub-
scale internal consistency reliability was good (alpha 
0.74 to 0.92) with the exception of the two-item sub-
